Larimar Therapeutics (LRMR) Set to Release Earnings on Thursday

Larimar Therapeutics (NASDAQ:LRMR) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

Larimar Therapeutics (NASDAQ:LRMR) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.08. On average, analysts expect Larimar Therapeutics to post ($1.37) EPS for the current fiscal year and ($1.32) EPS for the next fiscal year.

Larimar Therapeutics Trading Up 2.7%

Shares of NASDAQ LRMR traded up $0.07 during trading hours on Tuesday, reaching $2.44. The stock had a trading volume of 75,636 shares, compared to its average volume of 2,409,196. The firm has a market cap of $252.96 million, a price-to-earnings ratio of -1.25 and a beta of 0.68. The business’s fifty day moving average price is $3.18 and its two-hundred day moving average price is $3.80. Larimar Therapeutics has a 52-week low of $1.91 and a 52-week high of $6.42.

Analysts Set New Price Targets

A number of brokerages have weighed in on LRMR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Wedbush lowered their target price on Larimar Therapeutics from $12.00 to $11.00 and set an “outperform” rating for the company in a report on Wednesday, August 5th. Finally, Leerink Partners started coverage on Larimar Therapeutics in a research report on Monday, September 14th. They set an “outperform” rating and a $13.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $10.33.

About Larimar Therapeutics

Larimar Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases.